曹 宇
  • 曹 宇

  • 职务:课题组长,特聘研究员
  • 电话:+1-713-245-9008
  • 邮箱:jiahua_cao@hotmail.com
  • 课题组主页:http://
  • 教育背景及工作经历
    2017-至今        北京大学深圳研究生院,课题组长,特聘研究员
    2016-2017        美国索伦托医疗制药(Sorrento Therapeutics Inc.),资深科学家
    2013-2016        斯克里普斯研究所 (导师: Peter G. Schultz), 助理研究员
    2007-2013        德克萨斯大学MD Anderson癌症研究中心 (导师: Michael G. Rosenblum), 博士后
    2001-2007        南开大学大学 (导师: 白钢),哲学博士
    1996-2000        辽宁大学, 理学学士
  • 研究兴趣

    近年来,免疫治疗已经被视为非常有前景的一种癌症治疗手段,而且一些免疫治疗药物已经被批准用于临床治疗,取得不错的治疗效果,不过仍然有很多药物停滞于临床前或者临床初期,其功效和安全性等有待提高。本课题组通过严格考察不同药物设计的抗肿瘤机理和潜在副作用等,旨在开发设计用于个性化治疗的精准药物开发策略。通过找到用于不同肿瘤的最佳设计方案,本课题组将开发新型药物开发平台并且设计新型的抗肿瘤药物,包括(i)新型免疫细胞策略,(ii)双特异型抗体以及(iii)多功能治疗分子。

  • 代表性成果

    1. Cao Y, Rodgers DT, Du J, Ahmad I, Hampton EN, Ma J, Mazagova M, Choi SH, Yun HY, Xiao H, Yang P, Luo X, Lim RKV, Pugh HM, Wang F, Kazane SA, Wright TM, Kim CH, Schultz PG, Young TS. Design of Switchable Chimeric Antigen Receptor T Cells Targeting Breast Cancer. Angewandte Chemie International Edition, 2016, 55 (26): 7520-7524. PMID: 27145250.

    2. Ma JSY*, Kim JY, Kazane SA, Choi SH, Yoon HY, Kim MS, Rodgers DT, Pugh H, Singer O, Sun SB, Fonslow BR, Kochenderfer JN, Wright TM, Schultz PG, Young TS, Kim CH, Cao Y* (Co-First Author), Versatile strategy for controlling the specificity and activity of engineered T cells. Proceedings of the National Academy of Sciences, 2016, 113 (4): E450-458. PMID: 26759368.

    3. Rodgers DT, Mazagova M, Hampton E, Cao Y, Ramadoss NS, Hardy I, Schulman A, Du J, Wang F, Singer O, Ma JSY, Nunez V, Shen J, Woods AK, Wright TM, Schultz PG, Kim CH, Young TS. Switch-Mediated Activation and Retargeting CAR T cells for B cell Malignancies. Proceedings of the National Academy of Sciences, 2016, 113 (4): E459-468. PMID: 26759369.

    4. Cao Y, Axup JY, Ma JSY, Wang RE, Choi SH, Tardif V, Lim RKV, Pugh HM, Lawson BR, Welzel G, Kazane SA, Sun Y, Tian F, Srinagesh S, Javahishvili T, Schultz PG, Kim CH. Multi-format T-cell engaging bispecific antibodies targeting human breast cancers. Angewandte Chemie International Edition, 2015, 54 (24): 7022-7027. PMID: 25919418.

    5. Kim MS, Ma JSK, Yun HY, Cao Y, Kim JY, Chi V, Wang D, Woods AK, Sherwood L, Caballero D, Gonzalez J, Schultz PG, Young TS, Kim CH. Redirection of Genetically Engineered CAR-T cells using Bifunctional Small Molecule Drug. Journal of the American Chemical Society, 2015, 137 (8): 2832-2835. PMID: 25692571.

    6. Wang RE, Liu T, Wang Y, Cao Y, Du J, Luo X, Deshmukh V, Kim CH, Lawson BR, Tremblay MS, Young TS, Kazane SA, Wang F, Schultz PG. An Immunosuppressive Antibody-Drug Conjugate. Journal of the American Chemical Society, 2015, 137 (9): 3229-3232. PMID: 25699419.

    7. Bull-Hansen B, Brandal MEB, Berg K, Cao Y, Skarpen E, Rosenblum MG, Weyergang A. Photochemical activation of MH3-B1/rGel; a HER2 targeted treatment approach for ovarian cancer. Oncotarget, 2015, 6 (14): 12436-12451. PMID: 26002552.

    8. Lim REV, Yu S,  Cheng B, Li S, Kim NJ, Cao Y, Chi V, Kim JY, Chatterjee AK, Tremblay MS, Schultz PG, Kazane SA. Targeted delivery of LXR agonist using a site-specific antibody-drug conjugate. Bioconjugate Chemistry, 2015, 26 (11): 2216-2222. PMID: 25945727.

    9. Cao Y, Marks JW, Liu Z, Cheung LH, Hittelman WN, Rosenblum MG. Design Optimization and Characterization of Her2/neu-Targeted Immunotoxins: Comparative In Vitro and In Vivo Efficacy Studies. Oncogene, 2014, 33 (4), 429-439. PMID: 23376850.

    10. Bull-Hansen B, Cao Y, Berg K, Rosenblum MG, Skarpen E, Weyergang A. Photochemical activation of the recombinant HER2-targeted fusion toxin MH3-B1/rGel; impact of HER2 expression on cytotoxic outcome. Journal of Controlled Release, 2014, 182: 58-66. PMID: 24637464.

    11. Furman JL, Kang M, Choi SH, Cao Y, Wold ED, Sun SB, Smider VV, Schultz PG, Kim CH. A genetically encoded aza-Michael acceptor for covalent crosslinking of protein-receptor complexes. Journal of the American Chemical Society, 2014, 136 (23): 8411-8417. PMID: 24846839.

    12. Zhou H, Mohamedali KA, Gonzalez-Angulo AM, Cao Y, Migliorini M, Cheung LH, Lobello J, Lei X, Qi Y, Hittelman WN, Winkles JA, Tran NL, Rosenblum MG. Development of Human Serine Protease-Based Therapeutics Targeting Fn14 and Identification of Fn14 as a New Target Overexpressed in TNBC. Molecular Cancer Therapeutics, 2014, 13 (11): 2688-2705. PMID: 25239934.

    13. Cao Y, Mohamedali KA, Cheung LH, Marks JW, Hittelman WN, Rosenblum MG. Construction and Characterization of Novel, Completely Human Serine Protease Therapeutics Targeting Her2/neu. Molecular Cancer Therapeutics, 2013, 12 (6): 979-991 (Journal Cover and Highlighted Article). PMID: 23493312.

    14. Mohamedali KA, Cao Y, Cheung LH, Hittelman WN, Rosenblum MG. The Functionalized Human Serine Protease Granzyme B/VEGF121 Targets Tumor Vasculature and Ablates Tumor Growth. Molecular Cancer Therapeutics, 2013, 12 (10): 2055-2066. PMID: 23858102.

    15. Cao Y, Marks JD, Huang Q, Rudnick SI, Xiong C, Hittelman WN, Wen X, Marks JW, Cheung LH, Boland K, Li C, Adams GP, Rosenblum MG. Single-chain antibody based immunotoxins targeting Her2/neu. Design optimization and impact of affinity on antitumor efficacy and off-target toxicity. Molecular Cancer Therapeutics, 2012, 11 (1): 143-153. PMID: 22090420.

    16. Cao Y, Marks JD, Marks JW, Cheung LH, Kim S, Rosenblum MG. Construction and characterization of novel recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies. Cancer Research, 2009, 69 (23): 8987-8995. PMID: 19934334.